BR0212989A - Métodos para tratamento neuroprotetor usando inibidores de inos seletivos - Google Patents
Métodos para tratamento neuroprotetor usando inibidores de inos seletivosInfo
- Publication number
- BR0212989A BR0212989A BR0212989-2A BR0212989A BR0212989A BR 0212989 A BR0212989 A BR 0212989A BR 0212989 A BR0212989 A BR 0212989A BR 0212989 A BR0212989 A BR 0212989A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- selective inhibitors
- treatment
- neuroprotective
- neuroprotective treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000000324 neuroprotective effect Effects 0.000 title abstract 3
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 229940119568 Inducible nitric oxide synthase inhibitor Drugs 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/961,521 US20030119826A1 (en) | 2001-09-24 | 2001-09-24 | Neuroprotective treatment methods using selective iNOS inhibitors |
| PCT/US2002/030214 WO2003026638A1 (en) | 2001-09-24 | 2002-09-24 | Neuroprotective treatment methods using selective inos inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0212989A true BR0212989A (pt) | 2005-04-26 |
Family
ID=25504581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0212989-2A BR0212989A (pt) | 2001-09-24 | 2002-09-24 | Métodos para tratamento neuroprotetor usando inibidores de inos seletivos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030119826A1 (enExample) |
| EP (1) | EP1429752A1 (enExample) |
| JP (1) | JP2005508910A (enExample) |
| KR (1) | KR20040039394A (enExample) |
| CN (1) | CN1556698A (enExample) |
| AU (1) | AU2002327042A2 (enExample) |
| BR (1) | BR0212989A (enExample) |
| CA (1) | CA2455989A1 (enExample) |
| IL (1) | IL161005A0 (enExample) |
| MX (1) | MXPA04002710A (enExample) |
| PL (1) | PL371774A1 (enExample) |
| WO (1) | WO2003026638A1 (enExample) |
| ZA (1) | ZA200402288B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| BRPI0617477A2 (pt) * | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
| CN101466379B (zh) | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | 稳定的拉喹莫德的制剂 |
| WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| AU2009288108B2 (en) * | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| BR112012002124A2 (pt) * | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| JP2016514162A (ja) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586474B2 (en) * | 2000-03-24 | 2003-07-01 | Pharmacia Corporation | Amidino compounds useful as nitric oxide synthase inhibitors |
| AR032318A1 (es) * | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
-
2001
- 2001-09-24 US US09/961,521 patent/US20030119826A1/en not_active Abandoned
-
2002
- 2002-09-24 IL IL16100502A patent/IL161005A0/xx unknown
- 2002-09-24 MX MXPA04002710A patent/MXPA04002710A/es unknown
- 2002-09-24 EP EP02761804A patent/EP1429752A1/en not_active Withdrawn
- 2002-09-24 PL PL02371774A patent/PL371774A1/xx not_active Application Discontinuation
- 2002-09-24 BR BR0212989-2A patent/BR0212989A/pt not_active IP Right Cessation
- 2002-09-24 WO PCT/US2002/030214 patent/WO2003026638A1/en not_active Ceased
- 2002-09-24 KR KR10-2004-7004170A patent/KR20040039394A/ko not_active Withdrawn
- 2002-09-24 CN CNA028185935A patent/CN1556698A/zh active Pending
- 2002-09-24 JP JP2003530275A patent/JP2005508910A/ja active Pending
- 2002-09-24 CA CA002455989A patent/CA2455989A1/en not_active Abandoned
- 2002-09-24 AU AU2002327042A patent/AU2002327042A2/en not_active Abandoned
-
2004
- 2004-03-23 ZA ZA200402288A patent/ZA200402288B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030119826A1 (en) | 2003-06-26 |
| CN1556698A (zh) | 2004-12-22 |
| PL371774A1 (en) | 2005-06-27 |
| CA2455989A1 (en) | 2003-04-03 |
| KR20040039394A (ko) | 2004-05-10 |
| MXPA04002710A (es) | 2004-07-05 |
| IL161005A0 (en) | 2004-08-31 |
| WO2003026638A1 (en) | 2003-04-03 |
| AU2002327042A2 (en) | 2003-04-07 |
| JP2005508910A (ja) | 2005-04-07 |
| ZA200402288B (en) | 2006-12-27 |
| EP1429752A1 (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9911666A (pt) | Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica | |
| BR9812753A (pt) | Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica | |
| BR0313282A (pt) | Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia | |
| BR0013122A (pt) | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| BRPI0013478B8 (pt) | medicamento compreendendo inibidor pde e uso de roflumilast | |
| BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| BR0306872A (pt) | Composições e métodos de tratamento envolvendo agonistas do receptor-gama ativado pelo proliferador de peroxissoma e inibidores seletivos da ciclooxigenase-2 | |
| BRPI0308663B8 (pt) | uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas | |
| BRPI0415753A (pt) | método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm | |
| WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
| MXPA04001397A (es) | Metodo y composiciones para el tratamiento y prevencion de dolor e inflamacion con un inhibidor selectivo de cicloxigenasa-2 y sulfato de condroitina. | |
| BR0311903A (pt) | Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico | |
| AU7862401A (en) | Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer | |
| BR0314300A (pt) | Aplicação de substâncias para a proteção da pele | |
| WO2005055956A3 (en) | Method for improving insulin sensitivity by administering an inhibitor of antitrypsin | |
| WO2005039483A3 (en) | Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity | |
| BR0317947A (pt) | Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes | |
| CO5210869A1 (es) | Una combinacion sinergetica: gabapentina y pregabalina | |
| BR0311180A (pt) | Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE 14/10/2008. |